Akers today is trading at $4.69, it went up with $2.79 from $1.9.
This is mainly because Akers Biosciences CEO Christopher Schreiber announced that they are one step closer to effective Coronavirus Vaccine Candidate. Akers stated that it has also initiated the second stage in protein expression, which most probably will provide an update later this month.
Akers also announced favorable clinical results for its BreathScan OxiCheck disposable breath test. OxiCheck determines the level of oxidative stress in the body by measuring the level of certain free radicals. This made the share go up because the test enables clinicians to monitor oxidative stress through the use of a mobile device through a new Bluetooth- enabled reading device from Akers.